kleo
pharmaceuticals
announces
data
presentation
novel
conjugation
platform
society
immunotherapy
cancer
sitc
annual
meeting
new
globe
newswire
kleo
pharmaceuticals
targeted
immunotherapy
company
developing
fully
synthetic
bispecific
therapies
redirect
enhance
replace
antibodies
announced
present
data
antibody
therapy
enhancer
conjugation
platform
upcoming
society
immunotherapy
cancer
sitc
annual
meeting
meeting
taking
place
virtual
format
november
details
poster
presentation
follows
abstract
title
novel
chemical
conjugation
technology
confers
antitumor
activity
via
native
fc
receptor
plasma
immunoglobulin
attaching
tumor
binders
abstract
number
authors
christian
vidal
phd
michael
cukan
phd
rajat
varma
phd
lawrence
iben
tanya
berbasova
phd
ada
vaill
ms
anna
bunin
phd
ann
marie
rossi
ms
david
trinh
bs
katy
mcgrath
bs
enrique
alvarez
dvm
matthew
welsch
phd
luca
rastelli
phd
session
title
chimeric
molecules
poster
presentations
wednesday
november
est
friday
november
est
virtual
poster
hall
posters
display
november
est
virtual
poster
hall
closes
december
kleo
mate
platform
enables
chemical
conjugation
therapeutic
antibodies
improve
existing
therapies
manner
mate
platform
also
used
develop
kleo
human
globulin
mimic
hgm
therapy
kleo
pharmaceuticals
kleo
pharmaceuticals
targeted
immunotherapy
company
develops
fully
synthetic
bispecific
therapies
redirect
enhance
replace
antibodies
company
founded
groundbreaking
research
scientific
founder
david
spiegel
yale
university
kleo
synthetic
immunotherapy
platform
uses
two
approaches
molecule
arm
multitargeted
antibody
therapy
enhancer
mate
help
redirect
stimulate
key
components
immune
system
eradicate
cancer
cells
virulent
pathogens
compared
biologic
therapies
kleo
compounds
smaller
versatile
allowing
better
tumor
tissue
penetration
improved
safety
higher
dose
levels
efficient
produce
potentially
orally
bioavailable
optimized
specified
biological
targets
combined
existing
therapies
kleo
investors
include
biohaven
pharmaceutical
holding
company
nyse
bhvn
peptidream
nikkei
pptdf
information
visit
contact
information
lifesci
advisors
investors
irina
koffler
ikoffler
susan
kinkead
media
susan
